The company had reported a net profit of Rs 195.06 crore in the April-June quarter of financial year 2013-14.
Cadila's net sales in the quarter under review were up by 25.68 per cent to Rs 2,020.38 crore as against Rs 1,607.45 crore in the year-ago period, the company said in a BSE filing.
"Sales growth was buoyed by the company's formulations business in the US, which grew by 88 per cent during the quarter," the company said in a statement.
Overall expenses in Q1 stood at Rs 1,741.71 crore, up 24.55 per cent, compared with Rs 1,398.38 crore in the same quarter of last fiscal.
Cadila Healthcare Ltd shares were trading at Rs 1,169 apiece in afternoon trade, up 3.53 per cent from previous close on the BSE.